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Background/aim: Based on our previous in vitro study with multilamellar liposomal bupivacaine (MLB) versus bupivacaine alone in
artificial cerebrospinal fluid, we aimed to investigate in vivo antinociceptive effect of intrathecal MLB by determining tail flick latency
(TFL) time after thermal stimulation in rats.
Materials and methods: After preparing MLB and high-yield drug entrapment in liposome (HYDEL) bupivacaine, 18 female Wistar
rats were assigned to 3 groups as control (bupivacaine) and study groups (MLB and HYDEL bupivacaine) including 6 rats in each
group to administer these drugs intrathecally. Antinociceptive activity was determined in terms of TFL time after thermal stimulation.
Maximum possible effect (MPE) calculated from TFL times and rats with motor block were documented.
Results: TFL times after intrathecal injection of HYDEL bupivacaine were significantly longer than that of the control and MLB groups
(P < 0.05) and returned to baseline 180 min after intrathecal injection. MPE (100%) with intrathecal HYDEL bupivacaine occurred
between 10 to 45 min. Afterwards, MPEs were 70% and 50% for the control and MLB groups, respectively. Motor block disappeared
after 20 min in the study groups while it lasted 75 min in the control.
Conclusion: Intrathecal administration of MLB and HYDEL bupivacaine in rats resulted in longer duration of antinociceptive activity
with shorter motor block duration.
Key words: Extended release formulation, liposomal bupivacaine, intrathecal, rat

1. Introduction
Experimental and clinical studies with long-acting amidtype local anesthetics encapsulated into liposomes have
been conducted to provide a prolonged local anesthetic
effect, a reduction of the plasma peak drug concentration,
and the safe administration of larger doses, which further
prolongs the duration of analgesia. All these studies with
liposomal local anesthetics have been done by either
epidural administration or local infiltration (1,2).
We previously showed the in vitro slow releasing pattern
of multilamellar liposomal bupivacaine (MLB) when
compared to bupivacaine alone as control in the artificial
cerebrospinal fluid (CSF) (3). Based on our previous in
vitro study, we hypothesized that an MLB formulation
might produce a longer antinociceptive effect associated
with differential block as compared to bupivacaine alone.
So far, no study has been conducted by injecting liposomal

local anesthetics in the intrathecal space. Therefore, we
aimed to investigate the possible in vivo antinociceptive
effect of intrathecal liposomal bupivacaine by determining
tail flick latency (TFL) time after thermal stimulation in
rats.
2. Materials and methods
The study was approved by the Institutional Animal
Care and Use and Ethics Committee of Gazi University
(Research Project Number: G.U.E.T-13.043.29/05/13)
and conducted at the Pharmacology and Pharmaceutical
Technology Research Laboratories of Faculty of Pharmacy
at Gazi University.
2.1. Preparation of liposome formulations
Structurally multilamellar liposomes were prepared from
dipalmitoyl phosphatidyl choline (DPPC)-cholesterol in
50% ratio using the dry-film hydration by vortex mixer
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(Firlabo, Lyon, France) as described by Serikawa et al.
(4) and Kajiwara et al.(5) Twenty mg of DPPC (Sigma,
St. Louis, MO, USA), 20 mg of cholesterol (Sigma), 50
mg (10 mL) of bupivacaine HCl (Bustesin 0.5% flacon,
Vem, İstanbul, Turkey), and 6 mL of methanol (Merck,
Germany) were kept ready to use (3). Then, two different
formulations were prepared as MLB and high-yield drug
entrapment in liposome (HYDEL) Bupivacaine (6,7).
2.1.1. Preparation of MLB
Step 1: 20 mg of DPPC, 20 mg of cholesterol, and 6 mL of
methanol were distillated in the rotavapor device (Büchi
Rotavapor R-200, Flawil, Switzerland). Solvent containing
methanol was removed at 340 mbar pressure where water
bath (Nuve BM 402, Ankara, Turkey) temperature was 60
°C and cooler water bath temperature was 10 °C. After
adding 10 mL of bupivacaine 0.5% (50 mg), the resulting
precipitation was kept for 30 min in the ultrasonic bath
(Bandelin Sonorex, Berlin, Germany) to provide a
homogeneous distribution.
2.1.2. Preparation of HYDEL bupivacaine
Step 1 was followed by washing liposomes by centrifugation
(Jouan MR 1822, Danfoss, Slovenia) at 10,000 ×g for 15
min to prepare HYDEL bupivacaine. Nine mL of the
liquid was removed from the tube, while the remaining
part was vortexed in the ultrasonic bath for 15 min to
achieve homogenous suspension.
2.2. Experimental protocol
Eighteen Wistar female rats weighing between 250 and
300 g were randomly assigned to 3 groups as indicated
below:
Control group (n = 6): 0.5% bupivacaine HCl,
MLB group (n = 6),
HYDEL bupivacaine group (n = 6).
The rats were kept ready to administer sevoflurane
(Sevorane®, AbbVie, İstanbul, Turkey) soaked gauze that
may allow them to awake within approximately 3 min.
Then, 30 µL of one of the formulations was injected into
the intrathecal space with a sterile disposable h 26 gauge
½ inch hypodermic needle (AYSET, Adana, Turkey) at
lumbar region after achieving a positive indication of
electrical shock-like tail movement as described (8).
2.3. Assessment of antinociceptive effect
Analgesia was assessed by determining TFL time using
tail flick device (Figure 1) (9).
2.3.1. Measuring TFL time
Thermal stimulation (54 °C) was applied to 3–4 cm
proximal part of the tail of the rats placed on the Tail-Flick
device (Ugo Basile 37360, Geminio, Italy). Time elapsed
from the onset of stimulation to tail flick was defined as
TFL time in seconds (s). Cut-off time was accepted as
12 s (9). Mean TFL was found to be approximately 3–4 s
and considered the baseline for the present study. Then,
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Figure 1. Rat on the tail flick device

baseline TFL (before study onset) and after intrathecal
administration of study drugs were recorded at 10, 20, 30,
45, 60, 75, 90, 120, 150, 180, 240, and 300 min.
2.3.2. Maximum possible effect
The TFL was converted to percent maximum possible
effect (MPE) for each group.
It was calculated dividing baseline TFL by cut off
baseline and the result is multiplied by 100%) (9).
MPE = (Baseline TFL) × 100%
(Cut-off baseline)
2.4. Assessment of motor function
Motor function of the lower extremity was assessed by
allowing each rat to walk on the table at 10, 20, 30, 45, 60,
75, 90, 120, 150 180, 240, and 300 min and recorded.
Motor block degree was evaluated as complete, partial,
or no block at all (10):
· Zero degree (complete block): rats cannot walk/
move,
· 1st degree (partial block): rats can hardly walk/move,
· 2nd degree (no motor block at all): rats can move/
walk.
2.5. Termination of the study
Animals were sacrificed by intraperitoneal injection of
thiopentone of 120 mg kg−1 24 h after the study.
2.6. Statistical analysis
All variables were expressed as mean ± standard error
of mean (SEM). After descriptive statistics, repeated
measures ANOVA was used within each group. Multiple
comparisons between every two groups were made by
Student’s t-test.
Data of the study showed normal distribution when
analyzed by the computer program GraphPad Prism
(version 5.00 for Windows: GraphPad Software, San
Diego, CA, USA). A P-value less than 0.05 was considered
statistically significant.
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3. Results
3.1. Antinociceptive effect
3.1.1. The TFL time
The changes in TFL over time in control versus study groups
(MLB and HYDEL bupivacaine) were displayed in Figure 2.
Predetermined cut-off time (12 s) was achieved in 10 min
in all groups. However, it persisted until 45 min only in the
HYDEL bupivacaine group.
The TFL times were significantly longer in the HYDEL
group when compared to MLB group at all measurement
intervals between 60 and 300 min after intrathecal
injection.
Significantly longer TFL times in the HYDEL group vs
the control group were observed at 60, 120, 150, 180, 240,
and 300 min after intrathecal injection (P < 0.05).
Approximately 180 min after intrathecal injection, TFL
times returned to cut-off time and persisted until the end
of 300 min (Figure 2).
Therefore, TFL times in HYDEL group recorded at
60, 120, and 150 min (11, 6, and 5 s, respectively) were
considered significant when compared to both the MLB
and control groups (P < 0.05) (Figure 2).
3.1.2. The MPE
The MPEs of the 3 groups over time were displayed
in Figure 3. The MPEs were significantly longer in the
HYDEL bupivacaine group when compared to the MLB
group at all measurement intervals between 60 and 300
min after intrathecal injection (P < 0.05).

Significantly longer MPE rates in the HYDEL
bupivacaine group than those of the control group were
observed at 60, 120, 150, 180, 240, and 300 min after
intrathecal injection (P < 0.05). Then, MPEs recorded at
240 and 300 min declined to zero.
3.2. Motor function
Rats with complete or partial motor block (0 or 1st degree)
over time after intrathecal administration are shown in
Figure 4. Approximately 70% of rats had complete or
partial motor block at 10 min and there was no motor block
at 75 min in the control group, whereas approximately
35% of the rats had complete or partial motor block at 10
min and there was no motor block at 20 min in both the
MLB and HYDEL groups.
4. Discussion
In the current in vivo study, primarily, the antinociceptive
effect of MLB versus control after the intrathecal
administration was demonstrated in rats. Secondly,
HYDEL bupivacaine was found to be a superior
formulation than MLB.
Liposomal bupivacaine was used with different
routes in the management of postoperative pain relief in
experimental and clinical studies. It was effectively used
for postoperative analgesia either by local infiltration in
humans or extradurally in rabbits (1,2). The first study
demonstrated that the distribution of extradural effect of
MLB was less than that of plain bupivacaine, while the

Figure 2. Tail flick latency times after intrathecal administration of MLB and HYDEL bupivacaine versus control in rats (n=6 in each
group). HYDEL= High Yield Drug Entrapment in Liposome. *:P<0.05 versus control group #:P<0.05 versus MLB group
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Figure 3. Maximum Possible Effect (MPE) indicated over time after intrathecal administration of MLB and
HYDEL bupivacaine versus control in rats (n=6 in each group). *:P<0.05 versus control group #:P<0.05
versus MLB group

radioactivity in the lumbar spinal nerves peaked in the first
hour and remained higher after 4 h when compared with
plain bupivacaine in rabbits (2). Afterwards, liposomal
bupivacaine was shown to be effective for treating
postoperative pain after burniectomy and hemoroidectomy
when used via local infiltration compared to placebo in
humans (1).
Hereby, we have demonstrated the in vivo
antinociceptive effect after intrathecal administration of
either MLB or HYDEL bupivacaine due to their extended
release pattern in rats. Antinociceptive effect of HYDEL
bupivacaine in terms of TFL time and MPE was superior
to MLB. Motor block duration was shorter with both
MLB and HYDEL bupivacaine than that of control.
The underlying mechanism of faster return of motor
function might be the in vivo slow releasing pattern of
the liposomal drugs in the intrathecal space.
EXPAREL (bupivacaine in combination with proven
product delivery platform, DepoFoam®) is a controlled
release formulation that is prepared by multivesicular
technology. Multivesicular liposomes (MVL) are different
from either unilamellar or multilamellar ones. The MVL
are larger than the traditional unilamellar (<1 μm) and
multilamellar (1–5 μm) liposomes. Depofoam, which is
an MVL preparation, has a nonconcentric multiple lipid
lay
er, while multilamellar liposomes have concentric
lipid bilayers (11–13). The present in vivo investigation
is the first experimental study that demonstrated the in
vivo extended release pattern of structurally MLB after
intrathecal administration in rats. We determined the
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antinociceptive activity by recording TFL time after
thermal stimulation in anesthetized rats that received
either intrathecal MLB or HYDEL bupivacaine.
In humans, only a single dose of liposomal bupivacaine
for wound infiltration to provide postoperative pain relief
is FDA-approved (14). In healthy volunteers, the effects
of epidural administration of a single dose of DepoFoam
formulation revealed a long lasting sensory block without
prolongation in motor block (15).
Long ago, determination of antinociceptive effect
of local anesthetics without liposomes after intrathecal
administration in rats was represented by MPE (9).
Similarly, we used MPE to compare the antinociceptive
effects. We observed a significantly higher MPE with
HYDEL bupivacaine than those of the MLB and control
60 min after intrathecal use. Additionally, 100% MPE
with HYDEL bupivacaine was observed between 10 and
45 min after intrathecal use. Interestingly, simultaneous
mean MPEs at 45 min after intrathecal administration
were 70% and 50% for the control and MLB groups,
respectively. Based on these findings, HYDEL bupivacaine
had the greatest antinociceptive effect. We assumed that
the concentric lipid bilayer of the HYDEL bupivacaine
formulation might have played a more important role in
the extended release pattern by limiting the drug release
to a much greater extent than MLB.
In studies with local anesthetics only (without
liposomes), 100% MPEs obtained from either 0.5%
bupivacaine or 0.5% levobupivacaine lasted half an hour
(9), whereas 90% MPE of HYDEL bupivacaine lasted
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Figure 4. Percentage of rats with complete or partial motor block (zero or 1st degree) over time
after intrathecal administration of MLB and HYDEL bupivacaine versus control in rats (n=6 in
each group). BTF: Before Tail flick *:P<0.05 versus control group #:P<0.05 versus MLB group

300 min (5 h) and then MPE became 0%. Therefore, we
discontinued data collection and recording after 5 h.
Additionally, 70% of the rats in the control group and 30
% rats in the study groups had complete or partial motor
block at 10 min. Motor block disappeared at 75 min
and 20 min in the control and study (MLB and HYDEL
Bupivacaine) groups, respectively.
We previously showed that bupivacaine was released
from all liposomal bupivacaine formulations in vitro (3).
The release rates were slower depending on liposomal
formulations, which might be because of the controlled
release of active substance by the liposome’s lipid bilayers.
When liposomes were separated and redispersed, the
drug content decreased. Therefore, the total released drug
was found to be low. However, when the outer medium
also contained the study drug, total release was found to
be high. In all formulations, the lipid wall of liposome
limited the drug release, which revealed that the lipid
bilayer could have played an important role (3).
Despite the concerns, injection of pharmacologically
active liposomal bupivacaine into brachial plexus did not
result in neurotoxicity (16). When rabbits were assigned
into 5 groups (n = 6 in each) to be injected intrathecally 0.3
mL of NaCl solution (control), 2% tetracaine,
10% lidocaine, 2% bupivacaine, or 2% ropivacaine, the
sensory and motor functions in the lidocaine group were
significantly worse than in the other groups. The extent
of characteristic histopathologic vacuolation of the dorsal
funiculus and chromatolytic damage of motor neurons was
lidocaine = tetracaine > bupivacaine > ropivacaine (17).

These results may be promising, if intrathecal
extended release profiles are reproduced successfully by
using MLB.
Recently,
the
potential
role
of
liposomal
bupivacaine
as
an
extended
release bupivacaine has been reviewed not only in chronic
pain states but also in epidural and intrathecal practice
(15,18–20).
In
healthy
volunteers,
epidural
administration of liposomal bupivacaine provided
longer duration of sensory block with shorter duration
of motor block than nonliposomal bupivacaine and
intradermal injection of multivesicular form produced
a prolonged duration of analgesia in a dose-dependent
manner (15,19). Another study with MLB in rats
showed that there was an 8-fold increase versus placebo
in the duration of wound analgesia (20). To the best of
our knowledge, no prior comparative study has been
conducted on the intrathecal use of MLB formulations
to demonstrate the extended controlled release profile
in vivo until now. This is the first study to show in
vivo extended antinociceptive efficacy after intrathecal
injection in rats.
In conclusion, intrathecal administration of MLB
and HYDEL bupivacaine in rats resulted in longer
duration of antinociceptive activity with shorter motor
block duration.
Therefore, these results are encouraging for providing
prolonged neuraxial analgesia and/or anaesthesia with
single injection of these bupivacaine formulations in the
future.
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